The analyses in this paper complement previous studies showing the potential to use genomic breakpoints for BCR-ABL1 [7]; KMT2A-rearrangements [8, 9]; and CDKN2A/B deletions [30] as MRD markers in ALL. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.